Siglec-15 Protein, Cynomolgus (HEK293, His-Avi)

Cat. No.:	HY-P78353
Synonyms:	CD33 molecule-like 3; CD33L3; HsT1361; Siglec15; CD33 antigen-like 3; SIGLEC-15
Species:	Cynomolgus
Source:	HEK293
Accession:	A0A2K5UY47 (F20-T263)
Gene ID:	102126346
Molecular Weight:	33-43 kDa

PROPERTIES

Biological Activity	Immobilized Cynomolgus Siglec-15, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-Siglec-15 Antibody, hFc Tag with the EC_{50} of 16.7ng/ml determined by ELISA.
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 500 mM NaCl, 0.1M L-arginine, pH 6.0. Normally 5% trehalose is added as protectant before lyophilization.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in 20mM PB, 0.5M NaCl, 5% glycerol, 0.1M L-Arginine, pH 6.0.
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	Siglec-15, a Siglec family member and type-1 transmembrane protein, is constitutively expressed in osteoclasts, macrophages and dendritic cells. Siglec-15 acts upstream of or within regulation of actin cytoskeleton organization. Siglec-15 deficiency can promote bone formation and reduce bone resorption, indicating that Siglec-15 plays a pivotal role in the development and differentiation of osteoclastogenesis and may serve as a target to inhibit bone resorption and promote bone remodeling that increases bone mass. Siglec-15 is a predominantly macrophage-mediated suppressor of T cell responses. In tumors, Siglec-15 is negatively regulated by IFN-γ, thus influencing effector T cell-mediated antitumor immunity. Genetic ablation or antibody blockade of Siglec-15 amplifies anti-tumor immunity in the TME and inhibits tumor growth in some mouse models. Siglec-15 as a potential target for normalization cancer immunotherapy[1][2][3][4].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA